Published on 8 Jun 2016
The third patient in stem cell specialist ReNeuron Group Plc’s (LON:RENE) early-stage clinical trial treating people with a rare eye disease will receive the therapy next week.
Researchers at Massachusetts Eye and Ear in Boston are using human retinal progenitor cells (hRPC) to possibly halt the progression of retinitis pigmentosa (RP).
Michael Hunt, chief financial officer, tells Proactive Investors “it’s important because the third patient marks the end of the first dose cohort in this particular study…so that’s good progression”.
They are carrying out a phase I/II clinical study on 15 acute sufferers of the degenerative conditions, and hunt says he expects the rest to be completed “over the course of this and possibly a little bit into next year” depending on the recruitment process.
www.proactiveinvestors.co.uk › LON:RENE
EXECUTIVE INTERVIEW: $RENE discusses #cell-based technology platforms & potential #clinical data #catalysts #pharma https://t.co/If7dkyebxA— Edison (@Edison_Inv_Res) October 22, 2014